| Literature DB >> 24886191 |
Leah T Coles1, Elly A Fletcher, Claire E Galbraith, Peter M Clifton.
Abstract
BACKGROUND: Offering the overweight or obese patient the option of choosing from a selection of weight loss diets has not been investigated in type 2 diabetes. The aim of the study was to investigate if the option to choose from, and interchange between a selection of diets ("Choice"), as opposed to being prescribed one set diet ("No Choice"), improves drop out rates and leads to improved weight loss and cardio-metabolic outcomes.Entities:
Mesh:
Year: 2014 PMID: 24886191 PMCID: PMC4035903 DOI: 10.1186/1479-5868-11-64
Source DB: PubMed Journal: Int J Behav Nutr Phys Act ISSN: 1479-5868 Impact factor: 6.457
Baseline characteristics for all participants who enrolled in a 12 month weight loss trial
| | |||
|---|---|---|---|
| Age (years) | 58.3 ± 7.4 | 58.5 ± 6.9 | 58.0 ± 7.9 |
| Weight (kg) | 100.7 ± 17.6 | 100.6 ± 18.6 | 100.7 ± 16.7 |
| BMI (kg/m2) | 34.9 ± 5.4 | 35.0 ± 5.5 | 34.9 ± 4.8 |
| HbA1c (%) | 7.1 ± 1.3 | 7.1 ± 1.2 | 7.2 ± 1.4 |
| Pre-diabetes ( | 24 | 11 | 13 |
| Diabetes ( | 120 | 62 | 58 |
| Male ( | 78 | 38 | 40 |
| Female ( | 66 | 35 | 31 |
1Data are means ± SD.
There was no significant difference between participants in the Choice versus the No Choice group for any variable or characteristic using one-way ANOVA.
HbA1c: glycosylated haemoglobin.
Figure 1CONSORT-style flow chart.
Figure 2Weight change (kg) from baseline by diet group and gender. A. Shows only those participants who completed the 12 month weight loss program. B. Shows weights for all participants enrolled at baseline with weights carried forward from last known measurement for participants who discontinued the weight loss program. Data are means, error bars represent SE. P-values determined using repeated measures ANOVA. Participant numbers were: A. No Choice – women (n = 21) and men (n = 28); Choice - women (n = 18) and men (n = 29); and B. No Choice – women (n = 35) and men (n = 38); Choice women (n = 31) and men (n = 40).
Cardio-metabolic changes from baseline to 12 months for participants completing a 12 month weight-loss trial
| | ||||||
|---|---|---|---|---|---|---|
| SBP (mmHg) | 140.8 ± 18.1 | -6.4 ± 17.4§ | 142.9 ± 19.5 | -6.7 ± 17.5 | 138.5 ± 16.6 | - 6.2 ± 17.4 |
| DBP (mmHg) | 84 ± 10.8 | -3.9 ± 10.8§ | 85.0 ± 11.4 | -5.0 ± 10.1 | 82.7 ± 10.2 | -2.7 ± 11.6 |
| HbA1c (%) | 7.02 ± 1.26 | -0.15 ± 0.79 | 7.04 ± 1.28 | -0.19 ± 0.82 | 6.99 ± 1.26 | -0.11 ± 0.77 |
| Fasting Glucose (mmol/L) | 7.47 ± 2.28 | -0.42 ± 1.75§ | 7.51 ± 2.50 | -0.53 ± 1.94 | 7.41 ± 1.93 | -0.31 ± 1.53 |
| Triglycerides (mmol/L) | 1.79 ± 0.89 | -0.09 ± 0.89 | 1.85 ± 0.97 | -0.26 ± 0.76 | 1.73 ± 0.79 | 0.09 ± 0.98 |
| Total cholesterol (mmol/L) | 4.50 ± 1.13 | -0.01 ± 0.61 | 4.33 ± 0.94 | -0.05 ± 0.60 | 4.67 ± 1.29 | 0.03 ± 0.63 |
| HDL cholesterol (mmol/L) | 1.20 ± 0.45 | -0.05 ± 0.35 | 1.13 ± 0.24 | -0.01 ± 0.16 | 1.28 ± 0.59 | -0.09 ± 0.47 |
| LDL cholesterol (mmol/L) | 2.46 ± 1.01 | 0.12 ± 0.61 | 2.26 ± 0.89 | 0.15 ± 0.68 | 2.66 ± 1.10 | 0.08 ± 0.52 |
| hs-CRP (mg/L) | 2.96 ± 2.45 | -0.36 ± 1.84 | 3.15 ± 2.72 | -0.51 ± 2.13 | 2.76 ± 2.14 | -0.21 ± 1.49 |
1Data are means ± SD, shown only for those participants who completed the 12 month trial.
§There was no effect of diet group for any variable (repeated measures ANOVA), and no significant difference between baseline measures and those at 12 months for any variable for any diet group (All, No Choice or Choice) except for change in overall SBP (p < 0.001), DBP (p = 0.02) and fasting glucose (p = 0.02) (repeated measures ANOVA).
DBP: diastolic blood pressure, HbA1c: glycosylated haemoglobin, HDL: high-density lipoprotein, hs-CRP: high-sensitivity c-reactive protein, LDL: low-density lipoprotein, SBP: systolic blood pressure.